Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 13/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82026 | 0.92 | MAPK1 (0.40) | MTORPIK3CAMAPK1PAK1BTK | |
| SCHEMBL83680 | 0.77 | SYK (0.38) | MTORMAPK1 | |
| SCHEMBL5017318 | 0.73 | PIK3CA (0.48) | MTORPIK3CA | |
| SCHEMBL61800 | 0.72 | MTOR (0.40) | MTORPIK3CAMAPK1PAK1 | |
| SCHEMBL55757 | 0.72 | MTOR (0.40) | MTORPIK3CA | |
| SCHEMBL56588 | 0.71 | PIK3CA (0.62) | MTORPIK3CA | |
| SCHEMBL84228 | 0.71 | NAMPT (0.35) | MTORMAPK1BTK | |
| SCHEMBL54766 | 0.69 | PIK3CA (0.68) | MTORPIK3CA | |
| SCHEMBL82027 | 0.68 | SYK (0.37) | MTORPIK3CAMAPK1 | |
| SCHEMBL79935 | 0.68 | CSF1R (0.39) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | MTOR 1/4885PIK3CA 2/4885MAPK1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.